Output Of The Post Market Surveillance (PMS) Plan


The Need for PMS

Post Marketing Surveillance (PMS) are often defined because the process of identifying and gathering information concerning medications or medical devices after it's been approved by the concerned authorities like the Food and Drug Administration (FDA) within the US. With regards to medications, a scientific PMS process commenced way back within the early 1970s and since then, there has been a considerable increase in PMS. Drug and medical device monitoring following the method of approval has become mandatory for several reasons (FDA, 2020).
Way back within the past during the 1950s and 60s, the amount of medicine within the market were very scant compared to today which made monitoring a rather easy process. within the present day, drug manufacturing has assumed magnanimous proportions and is being consumed at a really high rate. Several other factors that warrant the necessity for PMS pertains to the modifications within the approval process of the FDA.


Though the method of approval has weathered harsh criticism, the FDA has countered the criticism by fixing opportunities and mediums for patients who are in need of critical drugs (Onakpoya et al., 2016). As an outcome, it'd not be possible to spot the risks (during the premarketing stage) involved in using certain drugs.

Post market surveillance is executed by several different organization types, also as agencies. These would comprise of universities, private organizations, pharmaceutical manufacturers and consumer advocacy groups. the target of completing a PMS might vary from case-to-case and on the idea of the point of view of the personnel who would be responsible to execute the surveillance (Pane et al., 2019). Recent instances in terms of questions of safety within public health that revolved around medical devices have also accorded much emphasis on the need to reinforce the ecu Union medical device regulation (EU-MDR). This was particularly in response to the general public health concern that arose in 2012 from hip implants.

Total metal-on-metal hip replacements were administered effectively amongst several patients. However, abrasions from metal-on-metal led to leaching and erosion of metallic particles into soft tissue (FDA, 2013). Thus, the metallic debris resulted in weakened bone and tissue round the implant and eventually caused the implant to fail and necessitated the necessity for further surgeries. within the same year, another instance that led to a scandal pertained to the poly implant prothese (PIP) breast implants. Women in more than 400,000 received these PIP breast implants which were manufactured using silicone gel of commercial grade. This industrial grade gel was susceptible to rupture and caused irritation and inflammation (New york daily News, 2012). This further advocated the necessity for PMS.

Post Marketing Surveillance

PMS: What it involves

Considering that the method of drug approval comprises of phase I clinical trial , II and III trials, post marketing trials are often mentioned as phase IV clinical trials trials. PMS comprises of a scientific monitoring of medicine and medical devices as they're utilized in actual real-world scenarios. this is often in contrast to controlled clinical settings during pre-marketing Clinical trials wherein the conditions of the study are strictly controlled (David & Kim, 2019). Though randomized clinical trials (RCTs) that have the propensity to lower variability are beneficial in evaluating the effectiveness of 1 drug or device as compared to the opposite , they seldom provide appropriate information on the consequences of the drug or device following its release within the marketplace for use by patients.

PMS: What it offers

PMS offers information which is very valuable with regards to utilizing drugs within special population of patients. the knowledge that's provided wouldn't be easily accessible from pre-marketing studies. Studies that involve an RCT that are executed before marketing comprise exclusively of subjects who match the preset exclusion and inclusion criterion, thereby creating a population that's largely homogenous (Suvarna, 2010). The population that creates up potential users following the drug or device being released within the market is extremely different from the population that has been evaluated during the phase of pre-marketing.

For instance, RCTs generally don't 
include women participants who are lactating or those that are pregnant. Therefore, PMS is merely the medium of acquiring information on teratogenic and mutagenic impact of medicine amongst humans (Jain & Rahul Chauhan, 2019). Other populations who stand to realize from PMS would comprise of patients having multiple comorbidities and therefore the elderly. like pregnant and lactating women, extremely old patients also are not included during pre-marketing trials. A drug might affect different populations during a different manner. for instance , a 30 year old healthy patient might show a special effect as compared to an 85 year old adult with multiple health issues.


PMS Plan Outputs

 EU-MDR, there's a requirement to possess a selected PMS plan for each product within an organization’s product portfolio. All medical devices of all classes are expected to possess a PMS plan whose scope would vary as per the complexity of the merchandise and therefore the risks it brings. the result of the activities concerning PMS would make an impression on the method of PMS during the lifecycle management of the device. Certain information derived from the PMS plan would be utilized to update other documents concerning PMS. An approach which is modular so as to structure the PMS plan contents would be highly beneficial in providing consistent updates to other information associated with PMS.

The outputs from the PMS plan would result or impact diverse post-market documents. as an example 
, following a review of national registries (an aspect of the Post Marketing Clinical Follow-up [PMCF] plan), it's possible that a manufacturer might recognize a replacement issue in terms of safety with the merchandise which could impact diverse post market documents; update to clinical evaluation report (CER), development of corrective and preventive actions (CAPAs), new training for users or submitting field safety corrective action (FSCA) (Pane et al., 2019).

Related Topics :

Relevant Medical Databases And Search Engines For Periodic Literature Screening

New Medical Device Regulation: Implications for Medical Device Manufacturers

Scientific Writing Services

Medical Device Regulatory Consulting Services

ClinicalTrial Services

Clinical Biostatistics Services

Regulatory Medical Writing Services


Comments

Popular posts from this blog

Difference between Clinical Research Organization and Contract Research Organization(CRO)?

TIPS FOR SCIENTIFIC MEDICAL WRITING

THE ROLE OF REFERENCING IN SCIENTIFIC WRITING